Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapses to interferon monotherapy

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 8, 1998, Pages 717-723

  Moreno Monteagudo, J A ^a   Fernandez Bermejo M ^a   Garcia Buey L ^a   Sanz, P ^a   Iacono, L O ^a   Garcia Monzon C ^a   Borque, M J ^b   Moreno Otero, R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Hospital de la Princesa ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; URIC ACID; VIRUS RNA;

ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTICLE; ASTHMA; CHILL; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SKIN DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VIREMIA;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031871454     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00359.x     Document Type: Article

References (24)

1. Di Bisceglie A, Goodman ZD, Ishak KG, Hoofnagle J, Melpolder J, Alter H. Long-term clinical and histopathological follow-up of chronic postransfusion hepatitis. Hepatology 1991; 14: 969-74.
2. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of hepatitis C. Am J Gastroenterol 1993; 88: 240-3.
3. Davis GI Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501-6.
4. Tinè F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-9.
5. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 82-91.
6. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994; 121: 276-7.
7. Cavalletto L, Chemello L, Casarin C, et al. Late reactivation of chronic hepatitis C after sustained biochemical response to interferon therapy. J Hepatol 1995; 23(Suppl. 1): 77.
8. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial. Hepatology 1997; 26: 473-7.
9. Serfaty L, Giral PH, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-7.
10. Marcellin P, Boyer N, Pouteau M, Benhamou JP, Erlinger S. Re-treatment with interferon-α of chronic hepatitis C virus infection. Lancet 1994; 344: 690-1.
11. Toyoda H, Nakano S, Takeda Y, et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89: 1453-7.
12. Chemello L, Bonetti P, Cavaletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
13. Gerken G, Teuber G, Goergen B. Meyer zum Büschenfelde KH. Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995: 22(Suppl. 1): 118-21.
14. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Inter Med 1995; 123: 897-903.
15. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23(Suppl. 2): 13-16.
16. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8.
17. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996; 3: 247-52.
18. Reichard O, Yun Z-B, Sönnerborg A, Weiland O. Hepatitis C viral titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 22: 1-4.
19. Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG, Williams R. Effects of ribavirin on intrahepatic and extra-hepatic expression of hepatitis C virus in interferon non-responsive patients. J Med Virol 1995; 45: 29-34.
20. Schalm SW, Brouwer JT, Chemello L, et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996; 41(Suppl. 12): 131S-134S.
21. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23(Suppl. 2): 17-21.
22. Main J. Future studies of combination therapy for chronic hepatitis C. Optimizing response rates for each hepatitis C population. J Hepatol 1995; 23(Suppl. 2): 32-6.
23. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-13.
24. Marazuela M, García-Buey L, González-Arranz B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol 1996; 44: 635-42.